Insider Selling: Quest Diagnostics Incorporated (DGX) Chairman Sells $6,406,857.60 in Stock

Quest Diagnostics Incorporated (NYSE:DGX) Chairman Stephen H. Rusckowski sold 59,235 shares of Quest Diagnostics stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $108.16, for a total transaction of $6,406,857.60. Following the completion of the transaction, the chairman now owns 220,049 shares in the company, valued at approximately $23,800,499.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Quest Diagnostics Incorporated (NYSE DGX) opened at 104.96 on Friday. The company has a 50-day moving average of $106.93 and a 200 day moving average of $105.25. Quest Diagnostics Incorporated has a one year low of $79.12 and a one year high of $112.97. The company has a market cap of $14.32 billion, a P/E ratio of 21.15 and a beta of 0.69.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.13. The firm had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. Quest Diagnostics had a net margin of 9.28% and a return on equity of 15.66%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.34 earnings per share. Equities research analysts predict that Quest Diagnostics Incorporated will post $5.69 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 18th. Shareholders of record on Tuesday, October 3rd will be paid a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a yield of 1.71%. The ex-dividend date is Monday, October 2nd. Quest Diagnostics’s dividend payout ratio is currently 36.29%.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/16/insider-selling-quest-diagnostics-incorporated-dgx-chairman-sells-6406857-60-in-stock.html.

A number of hedge funds have recently made changes to their positions in DGX. WFG Advisors LP raised its position in shares of Quest Diagnostics by 45.3% in the second quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock valued at $107,000 after purchasing an additional 301 shares during the period. Sun Life Financial INC increased its position in Quest Diagnostics by 14,142.9% during the second quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock worth $111,000 after acquiring an additional 990 shares during the period. YorkBridge Wealth Partners LLC increased its position in Quest Diagnostics by 1.5% during the first quarter. YorkBridge Wealth Partners LLC now owns 1,188 shares of the medical research company’s stock worth $127,000 after acquiring an additional 18 shares during the period. Parallel Advisors LLC increased its position in Quest Diagnostics by 16.1% during the first quarter. Parallel Advisors LLC now owns 1,279 shares of the medical research company’s stock worth $137,000 after acquiring an additional 177 shares during the period. Finally, Acrospire Investment Management LLC increased its position in Quest Diagnostics by 300.0% during the second quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock worth $178,000 after acquiring an additional 1,200 shares during the period. Hedge funds and other institutional investors own 87.07% of the company’s stock.

Several research analysts have issued reports on DGX shares. Zacks Investment Research lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Monday, May 22nd. Bank of America Corporation restated a “neutral” rating and issued a $110.00 price target (up previously from $105.00) on shares of Quest Diagnostics in a research report on Sunday, May 28th. ValuEngine upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday, June 2nd. Mizuho lifted their price target on shares of Quest Diagnostics from $115.00 to $122.00 and gave the stock a “buy” rating in a research report on Monday, June 5th. Finally, Canaccord Genuity restated a “buy” rating and issued a $118.00 price target on shares of Quest Diagnostics in a research report on Tuesday, June 13th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Quest Diagnostics presently has a consensus rating of “Buy” and an average price target of $111.09.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Insider Buying and Selling by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply